Rivaroxaban reduces stent thrombosis risk, study says

04/19/2013 | MedPage Today (free registration)

Adding the anticoagulant rivaroxaban to dual antiplatelet therapy decreased the chances of death and stent thrombosis among patients being treated for acute coronary syndrome, according to a study in the Journal of the American College of Cardiology. The findings were based on an analysis of a 9,631-patient subgroup of the ATLAS ACS 2-TIMI 51 trial.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA